A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19. (LEONARDO)

  • STATUS
    Recruiting
  • days left to enroll
    10
  • participants needed
    150
  • sponsor
    4Living Biotech
Send
Updated on 15 October 2022
See if I qualify

Summary

This phase IIb study, LEONARDO is a multicenter, randomized, double-blind, placebocontrolled, parallel group study, to assess the therapeutic efficacy and safety of Plerixafor in patients over 18 years of age,

  • with acute respiratory failure related to COVID-19 and
  • Recently admitted in ICU or equivalent structure (within 48 hours) for COVID-19 related respiratory failure
  • without invasive mechanical ventilation and
  • requiring oxygen support ≥ 5L/min to obtain a transcutaneous O2 saturation > 94% A total of 150 participants, will be randomized in a 2:1 ratio to receive either Plerixafor (n=100) or placebo (n=50) as a continuous IV infusion for 7 days (from D1 to D8) in addition to standard of care (e.g. glucocorticoids...).

Safety data will be reviewed by an independent Data and Safety Monitoring Board (DSMB) during the study.

Details
Condition COVID-19 Acute Respiratory Distress Syndrome, COVID-19
Treatment Placebo, Plerixafor 20 MG/ML [Mozobil]
Clinical Study IdentifierNCT05411575
Sponsor4Living Biotech
Last Modified on15 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female ≥ 18 years of age
Using contraceptive consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Willing and able to provide written informed consent (or provided by legally acceptable representative if he/she is present and if in line with local regulations)
Admitted in ICU within 48 hours before randomization for COVID-19 related respiratory failure. (ICU or equivalent medical structure according to country specificities e.g., Acute Respiratory Care Unit, High Dependency Care Unit if they can provide: continuous IV infusion,continuous ECG, respiratory rate, percutaneous oxygen saturation screen monitoring, high flow nasal oxygen)
Not requiring immediate (within 24-36 hours) invasive mechanical ventilation according to investigator's judgment
Confirmed pneumoniae due to SARS-CoV-2, Laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR (in nasopharynx or throat samples) or other commercial or public health assay in any specimen, performed within 2 weeks prior to randomization
Acute respiratory failure requiring oxygen support (≥ 5L/min) to achieve a transcutaneous oxygen saturation > 94%
Estimated glomerular filtration rate (eGFR) > 50 mL/min/1.73m2 by the CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration) equation

Exclusion Criteria

Pregnancy or breast feeding
Anticipated transfer to another hospital, which is not a study site within 72 hours of randomisation
Need for Invasive mechanical ventilation at time of inclusion
Evidence of uncontrolled bacterial pneumopathy or active infection other than SARS-Cov-2 (laboratory confirmation)
Primitive pulmonary arterial hypertension
Cardio-vascular co-morbidity
History of vascular ischemic events (myocardial infarction or stroke) or congestive heart failure or peripheral arterial disease
History or current significant cardiac rhythm disorders (e.g., ventricular tachycardia)
Known medical history of proven symptomatic postural hypotension
Known cancer (solid or blood) in the last 5 previous years or previous haematological
disorders (malignancies and other chronic conditions) or having received bone
marrow transplant
Inadequate haematological function defined by
Neutrophil count < 1.0 x 109/L
Haemoglobin < 9.0 g/dL (90 g/L)
Platelets < 100 x 109/L
Kaliemia < 3.5 mmol/L and/or total Calcemia < 2.2 mmol/L
Inadequate hepatic function defined by Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) > 3 x upper limit of normal (ULN) and/or Total bilirubin > 2 x ULN
Patients with known allergy to Plerixafor or its excipients
Previous (within 4 weeks) or current participation in another clinical study other than an observational study
Patients with auto immune disease treated or not
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note